She underwent left anterior descending artery stenting and mechanical circulatory support with venoarterial extracorporeal ...

Background. A 61-year-old man presented with shortness of breath and chest pain on exertion. He had been diagnosed as having hiatus hernia 2 years previously and was taking proton-pump inhibitors as ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Hypertension complicates oHCM management because vasodilators can aggravate dynamic LVOT obstruction, whereas myosin inhibition targets sarcomeric hypercontractility rather than afterload.

Boston, MA - A new study confirms that the presence of left ventricular outflow tract obstruction, occurring in about a quarter of patients with hypertrophic cardiomyopathy (HCM), is a "strong, ...

MANCHESTER — Mavacamten (Camzyos, Bristol Myers Squibb) continues to show promising results in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a consultant cardiologist said ...

Evidence indicates that anatomical and physiological phenotypes of hypertrophic cardiomyopathy (HCM) stem from genetically mediated, inefficient cardiomyocyte energy utilization, and subsequent ...

Physicians at the Minneapolis Heart Institute say they are the first in the world to successfully use a mitral clip as initial therapy in a small series of patients with severe heart failure due to ...

Mayo Clinic researchers have developed and externally validated an artificial intelligence (AI) model that can identify a ...

BRISBANE, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced positive topline data from the company’s Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for ...